Analysis of clinical TCGA low grade glioma and glioblastoma data shows BRD4 gene expression correlates with decreased survival only in IDHmut glioma, while BRD3 gene expression correlates with reduced patient survival only in IDHwt glioma. This evidence concerns the gene BRD4 and central nervous system cancer.